A plasma proteomics study identified protein patterns linked to Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia, reporting a 21-protein panel for distinguishing neurodegenerative disease signals in blood. The approach focuses on measurable plasma constituents rather than brain imaging or cerebrospinal fluid. The work describes discovery of blood plasma protein signatures that map to major dementia categories, with the panel intended to support disease detection and potentially stratification for trials. Investigators framed the panel as a blood-based route to marker development across overlapping neurodegenerative conditions. For biotech teams, the main implication is a scalable biomarker format: a multi-protein blood panel could be easier to deploy for screening and longitudinal monitoring than more invasive diagnostic pathways. Details of assay performance and validation cohorts are not included in the provided excerpt, but the headline outcome is the move toward a defined proteomic panel rather than single-marker candidates.